肠道激素多受体激动剂治疗代谢性疾病的研究进展

Progress of intestinal hormone multi-receptor agonists in the treatment of metabolic diseases

肠道内产生多种肠道激素,其中胰高血糖素样肽-1(GLP-1)受体激动剂具有降糖、减重、心血管保护等作用。以GLP-1为主、融合其他肠道激素的多受体激动剂在促进胰岛素分泌、增加机体产热和肝脏脂肪分解、抑制食欲等作用上相互加强,提高了降低血糖、减轻体重、改善脂肪代谢等方面的临床疗效。除了治疗2型糖尿病(T2DM)以外,肠道激素多受体激动剂还有望用于治疗肥胖症、非酒精性脂肪性肝炎(NASH)等代谢性疾病。

A variety of gut hormones are produced in the intestine,among which glucagon-like peptide-1 receptor agonists have glucose-lowering,weight-loss,and cardiovascular protective effects.Glucagon-like polypeptide-1-based multiple agonists fused with other intestinal hormones reinforce each other in promoting insulin secretion,increasing body thermogenesis and hepatic lipolysis,and suppressing appetite,improving clinical efficacy in lowering blood glucose,reducing body weight,and improving fat metabolism.In addition to the treatment of type 2 diabetes mellitus,intestinal hormone multiple agonists are expected to be used for the treatment of metabolic diseases such as obesity and nonalcoholic steatohepatitis.